Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
PRINCETON, N.J, 3 June 2022. Bristol Myers Squibb announced topline results from the Phase 3 Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-1) Immune Modulators clinical trial, sponsored by the National Institutes of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 3, 2022 Category: Pharmaceuticals Source Type: clinical trials
Immune Modulator Drugs Improved Survival for People Hospitalized with COVID-19
June 2, 2022 -- A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept– drugs widely used to treat certain autoimmune... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 2, 2022 Category: Pharmaceuticals Source Type: clinical trials
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Conditions: Myocarditis Acute; Cancer Interventions: Drug: Abatacept plus; Drug: Placebo Sponsors: Massachusetts General Hospital; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2022 Category: Research Source Type: clinical trials
